Castration-resistant prostate cancer correlates strongly with development of metastasis in men with PSA relapse following radical surgery for localized prostate cancer, but it occurs much sooner, and thus may provide an intermediate endpoint in clinical trials of new therapeutics.
In a study, men who underwent high-intensity focused ultrasound partial gland ablation for prostate cancer had excellent preservation of potency and continence.
In a retrospective study, addition of carboplatin to chemotherapy regimens improved survival in men with metastatic castration-resistant prostate cancer whose disease progressed on second-generation hormone therapy.
Study findings suggest that many men can be spared radiation therapy following radical prostatectomy for high-risk prostate cancer.
Men who receive first-line abiraterone or enzalutamide or first-line docetaxel treatment for metastatic castration-resistant prostate cancer have similar overall survival, a prospective, observational cohort study found.
